Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Novavax had been hoping to find a sizable sales opportunity by advancing a protein-based alternative to the messenger RNA ...
With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...
An abundance of evidence indicates the mRNA COVID-19 vaccines are remarkably safe and work well to protect against severe ...
Summer's rise in COVID-19 cases led to the approval of updated versions of vaccinations targeting recent strains for the 2024 ...
The fall booster shot will protect against some of the latest strains of the virus, including JN. 1 and KP. 2, Health Canada ...
About a week later, the agency authorized an updated version of Novavax’s protein subunit vaccine for people 12 years and older. The mRNA vaccines specifically target KP.2, a subvariant of JN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback